Change in Antithyroglobulin Antibody Levels is a Good Predictor of Responses to Therapy in Antithyroglobulin Antibody-Positive Pediatric Papillary Thyroid Carcinoma Patients

Table 1

Clinicopathological characteristics of all patients.

	Total	Tg negative	Tg positive
Age at diagnosis of DTC
≤15	13 (27.08%)	9 (29.03%)	4 (23.53%)	0.944
>15	35 (72.92%)	22 (70.97%)	13 (76.47%)
Sex
Female	44 (91.67%)	27 (87.10%)	17 (100%)	0.317
Male	4 (8.33%)	4 (12.90%)	0 (0%)
Number of thyroid surgeries
1	40 (83.33%)	27 (87.10%)	13 (76.47%)	0.589
>1	8 (16.67%)	4 (12.90%)	4 (23.53%)
Tumor diameter (cm)
≤2	24 (50.0%)	17 (54.84%)	7 (41.18%)	0.634
>2, ≤4	16 (33.33%)	9 (29.03%)	7 (41.18%)
>4	8 (16.67%)	5 (16.13%)	3 (17.64%)
Multiplicity
Single	26 (54.17%)	17 (54.84%)	9 (52.94%)	0.900
Multiple	22 (45.83%)	14 (45.16%)	8 (47.06%)
Extra-thyroidal extension
No	31 (64.58%)	22 (71.97%)	9 (52.94%)	0.212
Minimal/gross	17 (35.42%)	9 (29.03%)	8 (47.06%)
N stage
N0 or Nx	4 (8.33%)	3 (9.68%)	1 (5.88%)	0.902
N1a	11 (22.92%)	7 (22.58%)	4 (23.53%)
N1b	33 (68.75%)	21 (66.74%)	12 (70.59%)
Distant metastases
No	45 (93.75%)	30 (96.77%)	15 (88.24%)	0.585
Yes	3 (6.25%)	1 (3.21%)	2 (11.76%)
Initial risk stratification
Low	7 (14.58%)	5 (16.13%)	2 (11.74%)	0.406
Intermediate	17 (35.42%)	14 (45.16%)	5 (29.41%)
High	24 (50.00%)	12 (38.71%)	10 (58.82%)
With LT
No	25 (52.08%)	54.84 (%)	8 (47.06%)	0.606
Yes	23 (47.92%)	45.16 (%)	9 (52.94%)
Number of courses for ^131I therapy
1	40 (83.33%)	27 (87.10%)	13 (76.47%)	0.589
>1	8 (16.67%)	4 (12.90%)	4 (23.53%)
Cumulative dose of ^131I activities (mCi)
≤100	37 (77.08%)	25 (70.59%)	12 (80.65%)	0.664
>100	11 (22.92%)	6 (29.41%)	5 (19.35%)
sTg (ng/ml)
<1	32 (66.67%)	25 (80.65%)	7 (41.18%)	0.006
≥1	16 (33.33%)	6 (19.35%)	10 (58.82%)
sTgAb (IU/ml)
<500	27 (56.25%)	16 (51.61%)	11 (64.71%)	0.382
≥500	21 (43.75%)	15 (48.39%)	6 (35.29%)
TgAb trend
Decrease ≥50%	28 (58.33%)	18 (50.06%)	11 (64.71%)	0.653
Decrease <50% or increase	20 (41.67%)	13 (41.94%)	6 (35.29%)
TgAb clearance
Yes	23 (45.83%)	14 (45.16%)	9 (52.94%)	0.606
No	25 (54.17%)	17 (54.84%)	8 (47.06%)
Follow-up time	63.81 ± 31.25	57.81 ± 29.11	74.76 ± 32.90	0.086

sTg, stimulated Tg; sTgAb, stimulated TgAb; N, lymph node; LT, lymphocytic thyroiditis. .